MetIri is a two-stage single arm Phase II assessing the role of combination of metformin to irinotecan for colorectal cancer patients already treat with oxaliplatin, fluoropyrimidine, irinotecan and an anti-EGFr antibody if KRAS wild-type.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 years or older
Biopsy-proven colorectal adenocarcinoma
Ineligibility for curative intent therapy, e.g., surgery or radiation
Disease progression after oxaliplatin (either adjuvant or palliative), fluoropyrimidine (either adjuvant or palliative), irinotecan, and if Kras wild type a anti-EGFR therapy
Assessable disease according to RECIST v1.1
You may not be if
known hypersensitivity to metformin or irinotecan
Uncontrolled Central nervous system metastasis
Acute or chronic severe infection
Clareo Health | Metformin Plus Irinotecan for Refractory Colorectal Cancer
